Fibrosis is a major player in cardiovascular disease, both as a contributor to the
development of disease, as well as a post-injury response that drives progression. Despite …

Background Recent studies have shown that dysregulation of autophagy is involved in the
development of nonalcoholic fatty liver disease (NAFLD). Transcription factors E3 (TFE3) …

The activation of peroxisome proliferator-activated receptor α (PPARα) is a key
pharmacological drug target for dyslipidemic management. Dyslipidemia is associated with …

Herein, zinc oxide nanoparticles (ZnO NPs) were greenly synthesized from Tridax
procumbens aqueous leaf extract (TPE) and characterized physically (eg, Fourier-transform …

Aims Inflammation plays significant roles in developing diabetic nephropathy (DN).
Adenosine, natural purine nucleoside, acts as potent endogenous anti-inflammatory agent …

This study investigated the pretreatment and post-treatment effects of dipyridamole (20
mg/kg/day, po) in gentamicin-induced acute nephrotoxicity in rats. Rats were administered …

In the treatment process of hypertriglyceridemia and diabetic nephropathy in type 2
diabetes, fenofibrate (FEN) is a well-known medication. FEN is from fibrate class drugs that …

Peroxisome‐proliferator activated receptor‐alpha (PPARα) is a broadly expressed nuclear
hormone receptor and is a transcription factor for diverse target genes possessing a PPAR …

Aim. Diabetic nephropathy (DN) is the most frequent cause of end-stage renal disease. The
activation of the renin-angiotensin system (RAS) and lipid disorders are major risk factors in …

Computational Drug Repositioning (CDR) is the task of discovering potential new
indications for existing drugs by mining large-scale heterogeneous drug-related data …